Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.31% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.68M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta 76.34 | 52 Weeks Range 1.21 - 2.55 | Updated Date 08/29/2025 |
52 Weeks Range 1.21 - 2.55 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.38 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -1089.78% |
Management Effectiveness
Return on Assets (TTM) -66.42% | Return on Equity (TTM) -137.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1560510 | Price to Sales(TTM) 24.26 |
Enterprise Value 1560510 | Price to Sales(TTM) 24.26 | ||
Enterprise Value to Revenue 2.58 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 7978120 | Shares Floating 5626407 |
Shares Outstanding 7978120 | Shares Floating 5626407 | ||
Percent Insiders 24.02 | Percent Institutions 8.77 |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies, Inc. was founded to develop and commercialize cell and tissue therapies, particularly in orthopedics and metabolic disease. They focus on regenerative medicine approaches.
Core Business Areas
- Stem Cell-Based Therapies: Development of therapeutics using stem cells, focusing on areas like disc regeneration and metabolic disorders. Clinical trials and research are central to this segment.
Leadership and Structure
The company is led by a management team with experience in biotechnology and regenerative medicine. Specific details on the organizational structure would require direct review of their corporate governance documents.
Top Products and Market Share
Key Offerings
- BRTX-100: An autologous stem cell therapy targeting chronic lumbar disc disease. Currently in clinical trials. Market share is not yet established as the product is not commercially available. Competitors include companies developing similar regenerative therapies and traditional pain management options.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by increasing demand for therapies that address unmet needs in areas like orthopedics and metabolic diseases. Advances in stem cell technology and tissue engineering are fueling this growth.
Positioning
BioRestorative Therapies is positioned as a clinical-stage company focused on developing novel stem cell therapies. Their competitive advantage lies in their specific therapeutic targets and proprietary technology.
Total Addressable Market (TAM)
The TAM for regenerative medicine is estimated to be in the tens of billions of dollars, with specific segments like disc regeneration representing a significant portion. BioRestorative is aiming to capture a share of this market through its clinical programs.
Upturn SWOT Analysis
Strengths
- Proprietary stem cell technology
- Focus on unmet medical needs
- Clinical-stage programs
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
- High regulatory hurdles
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased funding and investment in regenerative medicine
Threats
- Clinical trial failures
- Regulatory delays
- Competition from established companies
- Patent disputes
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- MESO
- ATHX
Competitive Landscape
BioRestorative faces competition from established companies and other emerging players in the regenerative medicine space. Their success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily in terms of preclinical and clinical development of their stem cell therapies.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization of their products. Analyst estimates would be required for specific financial projections.
Recent Initiatives: Recent initiatives include ongoing clinical trials for BRTX-100 and exploration of new therapeutic applications for their stem cell technology.
Summary
BioRestorative Therapies is a clinical-stage biotech company with promising stem cell therapies. The company has great potential, but it is also very high risk. Positive clinical trial results are crucial for the company's survival, so potential future investors need to carefully monitor clinical trial results. The company also needs to be wary of competitors and potential threats that can affect its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Third-party market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own due diligence and assessment of risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.